{"meshTagsMajor":["Bile Ducts, Intrahepatic"],"meshTags":["Aged","Bile Duct Neoplasms","Bile Ducts, Intrahepatic","Cholangiocarcinoma","Diabetes Mellitus, Type 2","Hepatitis","Humans","Hypoglycemic Agents","Male","PPAR gamma","Thiazolidinediones"],"meshMinor":["Aged","Bile Duct Neoplasms","Cholangiocarcinoma","Diabetes Mellitus, Type 2","Hepatitis","Humans","Hypoglycemic Agents","Male","PPAR gamma","Thiazolidinediones"],"genes":["proliferator-activated receptor gamma","PPARgamma"],"organisms":["9606","9606"],"publicationTypes":["Case Reports","Journal Article"],"abstract":"Cholangiocarcinoma is a predominantly fatal cancer, which can be difficult to treat. We report a 73-year-old man who developed cholangiocarcinoma with cholangiohepatitis and diabetes. Administration of pioglitazone, peroxisome proliferator-activated receptor gamma (PPARgamma). agonist, improved not only diabetic control, but also the tumor-induced cholangiohepatitis, and improved the patient\u0027s quality of life. Although he finally died of obstructive jaundice, thiazolidinedione should be considered for treatment of tumor-induced hepatitis in the presence of diabetes, unless severe side effects occur.","title":"Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma.","pubmedId":"17938528"}